Verrica unveils positive data from VP-102 study in molluscum treatment

	Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast
	The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group


Verrica Pharmaceuticals Inc. – a U.S. based clinical-stage dermatology firm that develops medical solutions for viral skin diseases has reportedly announced positive results from a post-hoc pooled analysis of the vital Phase 3 CAMP clinical trials that assess the effectiveness and safety of VP-102 in the treatment of molluscum contagiosum.  

Apparently, the new results indicated that the total percentage of patients with zero infections or injuries was statistically considerably higher in the VP-102 group as compared to the vehicle, across all body regions.

According to Lawrence Eichenfield, MD, Chief of Pediatric and Adolescent Dermatology at Rady’s Children’s Hospital and primary investigator of the VP-102 stage 3 molluscum study was reportedly quoted stating that the analysis of the study is vital since it advises that the investigational treatment of molluscum can significantly lead to complete clearance, despite which part of the body is infected.

If approved, the medication can be a viable choice for physicians as they will have the option to treat even the most sensitive areas such as the neck, head and groin, he further added.

For the record, in the analysis of the CAMP studies, the intent-to-treat patient population had prevailing molluscum lesions in certain areas such as the neck, chest and abdomen, groin, upper extremities, back or buttocks and lower extremities. The effectiveness was calculated as per the percentage of subjects with complete clearance of infections in every location based on visits.

The data showcased a significant increase in the percentage of lesion clearance towards the end of the trial i.e. Day 84 across the entire body region calculated among the patients who received VP-102 as compared to vehicle.  

During the research, VP-102 safety results showcased similar adverse event rates across the entire body regions. Cases of application site Treatment-Emergent Adverse Events were calculated on the basis of pre-specified subset of application site reactions registered during or after Treatment Visit 1 and before the second Visit. The most common treatment-emergent adverse events consist of application site vesicles, dryness, pain, edema, pruritus, scab, erythema and discoloration.

 

Source Credits: https://investors.verrica.com/news-releases/news-release-details/verrica-pharmaceuticals-announces-presentation-positive-data-new